|
| Tuesday, 7 September 2010, 15:15 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, Sept 7, 2010 - (ACN Newswire) - SymBio Pharmaceuticals Limited and Eisai Co., Ltd. announced today that Eisai's Singapore subsidiary Eisai (Singapore) Pte. Ltd. launched bendamustine hydrochloride ("bendamustine") in Singapore under the brand name Symbenda(R) as a treatment for low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia.
Bendamustine is the subject of a license agreement concluded between the two companies in May 2009, in which SymBio granted Eisai the exclusive rights to develop and market the agent in Singapore and South Korea. A regulatory application seeking approval of bendamustine was submitted to the Singapore health authorities (Health Sciences Authority: HSA) by SymBio on December 24, 2008 and was approved on January 20, 2010. The product will be marketed by Eisai (Singapore) Pte. Ltd.
Approximately 300 people in Singapore are newly diagnosed with non-Hodgkin's lymphoma each year. It is well-known that many low-grade non-Hodgkin's lymphoma patients are prone to repeated relapse after responding to initial treatment, making further treatment difficult despite extended overall survival.
Bendamustine has been used for many years in Germany as a treatment for non-Hodgkin's lymphoma, multiple myeloma and chronic lymphatic leukemia. It is also available in the United States, where it was approved by the U.S. Food and Drug Administration in March 2008 for the treatment for chronic lymphatic leukemia and in October the same year for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma. In Japan, SymBio submitted a Marketing Authorization Application to the Japanese Ministry of Health, Labour and Welfare seeking approval of bendamustine for the treatment of recurrent or refractory low-grade non-Hodgkin's' lymphoma and mantle cell lymphoma. On August 30, 2010, the Pharmaceutical Affairs Committee of the Ministry's Pharmaceutical Affairs and Food Sanitation Council recommended bendamustine for final approval. If approved, Eisai will market the drug exclusively in Japan.
By launching bendamustine in Singapore, SymBio and Eisai seek to provide a new treatment option for low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia, thereby making further contributions to improving the quality of life of patients living with these diseases.
About Bendamustine Hydrochloride
SymBio Pharmaceuticals Limited acquired the exclusive rights to develop and market bendamustine hydrochloride in Japan, China, South Korea, Taiwan and Singapore from Astellas Deutschland GmbH (Headquarters: Munich, Germany, formerly Astellas Pharma GmbH). Bendamustine was originally synthesized by German (formerly 'East German') pharmaceutical company Jenapharm and is currently marketed in Germany under the brand name of Ribomustin(R) as a treatment for non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukemia. In the United States, the product has been approved by the U.S. Food and Drug Administration and is currently prescribed under the brand name Treanda(R) for the treatment of chronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin's lymphoma.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida, who previously served as corporate vice president of Amgen Ltd. and president of Amgen Japan. The company's underlying corporate philosophy is "delivering hope to patients in need," and the company aims to address the unmet medical needs of patients in Japan and the Asia Pacific region by cultivating a mutually beneficial or symbiotic relationship among key players in the healthcare industry (i.e. physicians, scientists, investors, government, and patients). For more information about SymBio Pharmaceuticals Limited, please visit www.symbiosis.co.jp/en/index.html.
Contact:
Tomoyuki Watanabe, Director,
Finance & Accounting
SymBio Pharmaceuticals Limited
Tel +81-3-5472-1125
Public Relations
Eisai Co., Ltd.
Tel +81-3-3817-5120
Topic: New market for product
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| May 21, 2026 23:23 HKT/SGT |
|
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026 |
| Apr 21, 2026 19:52 HKT/SGT |
|
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) |
| Mar 27, 2026 19:14 HKT/SGT |
|
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy |
| Mar 27, 2026 17:19 HKT/SGT |
|
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency |
| Mar 23, 2026 10:19 HKT/SGT |
|
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026 |
| Mar 19, 2026 09:54 HKT/SGT |
|
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide) |
| Mar 17, 2026 18:49 HKT/SGT |
|
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation |
| Mar 12, 2026 16:21 HKT/SGT |
|
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration |
| Mar 11, 2026 11:07 HKT/SGT |
|
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting |
| Mar 2, 2026 08:49 HKT/SGT |
|
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) |
| More news >> |
 |
|
|
|
